MYNZ
Mainz Biomed B.V.NASDAQHealthcare$0.70-5.07%ClosedMarket Cap: $2.9M
As of 2026-04-04
Valuation
P/E (TTM)
—
PEG
—
P/B
0.08
P/S
6.65
EV/EBITDA
-0.15
DCF Value
$-1.68
FCF Yield
-291.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.3%
Operating Margin
-2091.2%
Net Margin
-2421.8%
ROE
-465.8%
ROA
-163.5%
ROIC
-192.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $250.4K | 279.6% | $-8.0M | $-7.9M | $-0.05 | — |
| FY 2025 | $537.1K | 72.6% | $-16.1M | $-16.2M | $-2.70 | — |
| Q2 2025 | $286.7K | -108.2% | $-8.1M | $-8.3M | $-2.65 | — |
| Q4 2024 | $373.2K | 68.6% | $-8.9M | $-10.6M | $-7.71 | — |
| FY 2024 | $894.0K | 64.3% | $-18.7M | $-21.7M | $-22.36 | — |
| Q2 2024 | $520.8K | 61.3% | $-9.8M | $-11.0M | $-19.73 | — |
| Q4 2023 | $214.8K | 18.7% | $-12.2M | $-5.2M | $-11.73 | — |
| FY 2023 | $895.5K | 56.9% | $-26.6M | $-26.3M | $-1.62 | — |
| Q2 2023 | $500.2K | 55.6% | $-13.0M | $-13.3M | $-0.90 | — |
| Q4 2022 | $251.4K | 13.3% | $-12.3M | $-12.6M | $-0.89 | — |
| FY 2022 | $529.9K | 34.4% | $-26.4M | $-26.5M | $-1.87 | — |
| Q2 2022 | $278.5K | 53.4% | $-13.9M | $-13.9M | $-0.98 | — |